ABSTRACT OF THE DISCLOSURE

This invention provides a method of treating obesity, generalized anxiety disorder, post-traumatic stress disorder, late luteal phase dysphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome in a mammal by administering to the mammal an effective amount of a hydroxycycloalkanephenethyl amine of the following structural formula:

$$R_5$$
 R_6
 R_7
 R_1
 R_2

10 in which A is a moiety of the formula

where

20

5

the dotted line represents optional unsaturation;

R₁ is hydrogen or alkyl;

15 R₂ is alkyl;

R4 is hydrogen, alkyl, formyl, or alkanol;

R5 and R6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;

R7 is hydrogen or alkyl; and

n is 0, 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.